Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2019, Article ID 4828563, 11 pages
https://doi.org/10.1155/2019/4828563
Research Article

Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia

1School of Medicine, Western Sydney University, Penrith NSW 2751, Sydney, Australia
2School of Science and Health, Western Sydney University, Penrith NSW 2751, Sydney, Australia

Correspondence should be addressed to Endale G. Gebremedhn; ua.ude.yendysnretsew@nhdemerbeg.e

Received 10 May 2019; Revised 9 July 2019; Accepted 17 July 2019; Published 1 August 2019

Academic Editor: Francesca De Felice

Copyright © 2019 Endale G. Gebremedhn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. P. Kalofonos, G. Aravantinos, P. Kosmidis et al., “Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study,” Annals of Oncology, vol. 16, no. 6, pp. 869–877, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. André, C. Mounedji-Boudiaf, L. Navarro et al., “Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2343–2351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. L. Rothenberg, A. M. Oza, R. H. Bigelow et al., “Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial,” Journal of Clinical Oncology, vol. 21, no. 11, pp. 2059–2069, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. A. Argyriou, G. Cavaletti, C. Briani et al., “Clinical pattern and associations of oxaliplatin acute neurotoxicity,” Cancer, vol. 119, no. 2, pp. 438–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Grothey and R. M. Goldberg, “A review of oxaliplatin and its clinical use in colorectal cancer,” Expert Opinion on Pharmacotherapy, vol. 5, no. 10, pp. 2159–2170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Saadati and M. W. Saif, “Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer,” Journal of Pancreas, vol. 10, no. 4, pp. 459–461, 2009. View at Google Scholar
  7. A. A. Argyriou, P. Polychronopoulos, G. Iconomou, E. Chroni, and H. P. Kalofonos, “A review on oxaliplatin-induced peripheral nerve damage,” Cancer Treatment Reviews, vol. 34, no. 4, pp. 368–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. R. Pachman, R. Qin, D. K. Seisler et al., “Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance),” Journal of Clinical Oncology, vol. 33, no. 30, pp. 3416–3422, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. A. Argyriou, R. Velasco, C. Briani et al., “Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients,” Annals of Oncology, vol. 23, no. 12, pp. 3116–3122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. N. Pulvers and G. Marx G, “Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review,” Asia Pacific Journal of Clinical Oncology, vol. 13, no. 6, pp. 345–355, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. eViQ cancer treatment online, “Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin),” December 2018, https://www.eviq.org.au/medical-oncology/colorectal/metastatic/. View at Google Scholar
  12. A. Grothey, “Clinical management of oxaliplatin-associated neurotoxicity,” Clinical Colorectal Cancer, vol. 5, pp. S38–S46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. M. Beijers, F. Mols, and G. Vreugdenhil, “A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration,” Supportive Care in Cancer, vol. 22, no. 7, pp. 1999–2007, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. P. Chen, A. Setser, M. J. Anadkat et al., “Grading dermatologic adverse events of cancer treatments: the common Terminology criteria for adverse events version 4.0,” Journal of the American Academy of Dermatology, vol. 67, no. 5, pp. 1025–1039, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. National Institutes of Health and National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA, 2010, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
  16. E. G. Gebremedhn, P. J. Shortland, and D. A. Mahns, “The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review,” BMC Cancer, vol. 18, no. 1, p. 410, 2018. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Di Cesare, M. Maresca, L. Micheli et al., “A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin,” Cancer Chemother Pharmacology, vol. 80, no. 6, pp. 1091–1103, 2017. View at Google Scholar
  18. C. Rödel, T. Liersch, R. Fietkau et al., “Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial,” The Lancet Oncology, vol. 13, no. 7, pp. 679–687, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. D. N. Davidov, “Oxaliplatin/5-fluorouracil/leucovorin in the treatment of patients with metastatic colorectal cancer,” Journal of IMAB—Annual Proceeding (Scientific Papers), vol. 19, no. 3, pp. 476–480, 2013. View at Publisher · View at Google Scholar
  20. C. Rödel, U. Fietkau, W. Hohenberger et al., “Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial,” The Lancet Oncology, vol. 16, no. 8, pp. 979–989, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. R. J. Courtney, C. L. Paul, R. W. Sanson-Fisher et al., “Colorectal cancer screening in Australia: a community-level perspective,” Medical Journal of Australia, vol. 196, no. 8, pp. 516–520, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. C. J. Parkin, S. W. Bell, and N. Mirbagheri, “Colorectal cancer screening in Australia. An update,” Australian Journal of General Practice, vol. 47, no. 12, pp. 859–863, 2018. View at Google Scholar
  23. Council NC, Clinical Guideline for Cocorectal Cancer, NHMRC Council, Canberra, Australia, 2019, https://www.cancer.org.au/health-professionals/clinical-guidelines/colorectal-cancer.html.
  24. NHMRC, Bowel Cancer Screening Program in Australia, NHMRC Council, Canberra, Australia, 2019, http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/nbcsp-fact-sheet.
  25. A. Grothey, A. F. Sobrero, A. F. Shields et al., “Duration of adjuvant chemotherapy for stage III colon cancer,” New England Journal of Medicine, vol. 378, no. 13, pp. 1177–1188, 2018. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Grothey, A. F. Shields, T. Yoshino et al., “Duration of adjuvant chemotherapy for stage III colon cancer,” New England Journal of Medicine, vol. 379, no. 4, pp. 395–397, 2018. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Fakih, “The international duration evaluation of adjuvant chemotherapy study: implications for clinical practice,” Journal of Gastrointestinal Oncology, vol. 8, no. 4, pp. 603–607, 2017. View at Publisher · View at Google Scholar · View at Scopus
  28. T. André, T. Iveson, R. Labianca et al., “The IDEA (international duration evaluation of adjuvant chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status,” Current Colorectal Cancer Reports, vol. 9, no. 3, pp. 261–269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Aschele, L. Cionini, S. Lonardi et al., “Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial,” Journal of Clinical Oncology, vol. 29, no. 20, pp. 2773–2780, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. F. De Felice, D. Musio, A. L. Magnante et al., “Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience,” Clinical Colorectal Cancer, vol. 15, no. 2, pp. e17–e22, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. J.-P. Gérard, D. Azria, S. Gourgou-Bourgade et al., “Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1638–1644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Musio, F. De Felice, N. Bulzonetti et al., “Neoadjuvant-intensified treatment for rectal cancer: time to change?” World Journal of Gastroenterology, vol. 19, no. 20, pp. 3052–3061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. M. J. O’Connell, L. H. Colangelo, R. W. Beart et al., “Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04,” Journal of Clinical Oncology, vol. 32, no. 18, pp. 1927–1934, 2014. View at Publisher · View at Google Scholar · View at Scopus